Detail akcie Vir Biotechnolog Rg online

Business Summary: Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Vir Biotechnology Inc revenues decreased 93% to $4.5M. Net loss decreased 5% to $395.1M. Revenues reflect Contract revenue decrease of 94% to $3.4M, Grant revenue decrease of 82% to $1.7M. Lower net loss reflects Restructuring, long-lived assets impairm decrease from $39M (expense) to $182K (income), Research and development decrease of 5% to $348.1M (expense).